Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF‐based AcTakine targeted to CD13 enables selective activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Huyghe, Leander, Van Parys, Alexander, Cauwels, Anje, Van Lint, Sandra, De Munter, Stijn, Bultinck, Jennyfer, Zabeau, Lennart, Hostens, Jeroen, Goethals, An, Vanderroost, Nele, Verhee, Annick, Uzé, Gilles, Kley, Niko, Peelman, Frank, Vandekerckhove, Bart, Brouckaert, Peter, Tavernier, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709889/
https://www.ncbi.nlm.nih.gov/pubmed/31912630
http://dx.doi.org/10.15252/emmm.201911223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709889/
https://www.ncbi.nlm.nih.gov/pubmed/31912630
http://dx.doi.org/10.15252/emmm.201911223

Ejemplares similares